Back HCV Prevention HCV Vaccines

Hepatitis C Vaccine Is Safe and Induces Immune Responses in Early Human Trial

A new hepatitis C vaccine demonstrated good safely and tolerability in a first-in-humans Phase 1 clinical trial, with only mild and transient side effects, according to a report in the November 5 edition of Science Translational Medicine. The vaccine, which mimics immune responses in people who naturally clear hepatitis C virus (HCV) infection, led to increased production of T-cells targeting the virus. Phase 2 studies are now underway in Baltimore and San Francisco, with results expected in 2016.

alt

Read more:

EASL 2012: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap

Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

Scientists Find Antibodies that Neutralize Multiple Strains of Hepatitis C Virus

As described in a report published in the April 4, 2012, online edition of Proceedings of the National Academy of Sciences, Erick Giang and Mansun Law from the Scripps Research Institute and colleagues have identified a set of antibodies with activity against 5 different antigenic regions on the E1E2 complex of the hepatitis C virus (HCV) outer envelope.alt

Read more:

EASL 2012: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon

Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.alt

Read more:

Canadian Researchers Make Progress in Quest for Hepatitis C Vaccine

Researchers at the University of Albert say they have discovered a new vaccine candidate that stimulates immune response against all genotypes of hepatitis C virus (HCV). The variability of the virus enables it to elude the immune system and has so far hampered efforts to develop an effective vaccine.alt

Read more: